ifosfamide has been researched along with aprepitant in 14 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (35.71) | 29.6817 |
2010's | 6 (42.86) | 24.3611 |
2020's | 3 (21.43) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Durand, JP; Goldwasser, F; Gourmel, B; Mir, O | 1 |
Hatfield Seung, A; Howell, JE; Nesbit, SA; Szabatura, AH | 1 |
Jarkowski, A | 1 |
Romanick, M; Shiu, JR; Stobart, K | 1 |
Yuen, C | 1 |
Behlendorf, T; Jahn, F; Jahn, P; Jordan, K; Kegel, T; Ruessel, J; Schmoll, HJ; Stein, A | 1 |
Bärlund, M; Sunela, K | 1 |
Akashi, K; Arita, S; Ariyama, H; Baba, E; Harimaya, K; Inadomi, K; Kumagai, H; Kusaba, H; Matsunobu, T; Takayoshi, K | 1 |
Mohammadpour, AH; Rahimi, H; Sadeghi, M; Samadi, S; Vazirian, F | 1 |
Allal, B; Chaltiel, L; Chatelut, E; Chevreau, C; Filleron, T; Firmin, N; Lambert, M; Mseddi, M; Toulmonde, M; Valentin, T; Yakoubi, M | 1 |
Kawai, A; Kobayashi, E; Sano, T; Setsu, N | 1 |
3 review(s) available for ifosfamide and aprepitant
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Treatment and prevention of iphosphamide-induced encephalopathy].
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Drug Interactions; Enzyme Inhibitors; Humans; Ifosfamide; Methylene Blue; Morpholines; Neurotoxicity Syndromes | 2016 |
Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review.
Topics: Aprepitant; Humans; Ifosfamide; Morpholines; Neurotoxicity Syndromes; Randomized Controlled Trials as Topic; Retrospective Studies | 2022 |
1 trial(s) available for ifosfamide and aprepitant
Article | Year |
---|---|
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Granisetron; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Paclitaxel; Treatment Outcome; Vomiting; Young Adult | 2011 |
10 other study(ies) available for ifosfamide and aprepitant
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Diseases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Ifosfamide; Middle Aged; Morpholines | 2007 |
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
Topics: Antidotes; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Delirium; Female; Humans; Ifosfamide; Kidney Function Tests; Liver Function Tests; Male; Methylene Blue; Middle Aged; Morpholines; Neuropsychological Tests; Neurotoxicity Syndromes; Retrospective Studies; Sarcoma | 2008 |
Possible contribution of aprepitant to ifosfamide-induced neurotoxicity.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamethasone; Drug Therapy, Combination; Etoposide; Humans; Ifosfamide; Male; Morpholines; Nausea; Nerve Sheath Neoplasms; Neurotoxicity Syndromes | 2008 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in adolescents.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Cisplatin; Cyclophosphamide; Double-Blind Method; Drug Interactions; Etoposide; Fever; Humans; Ifosfamide; Incidence; Morpholines; Nausea; Neutropenia; Randomized Controlled Trials as Topic; Sample Size; Vomiting | 2009 |
Aprepitant-associated ifosfamide neurotoxicity.
Topics: Adult; Antidepressive Agents; Antineoplastic Agents, Alkylating; Aprepitant; Case-Control Studies; Female; Humans; Ifosfamide; Male; Middle Aged; Morpholines; Neurotoxicity Syndromes; Retrospective Studies; Sarcoma | 2010 |
Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Doxorubicin; Female; Humans; Ifosfamide; Male; Middle Aged; Morpholines; Nausea; Retrospective Studies; Sarcoma; Treatment Outcome; Young Adult | 2016 |
Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide.
Topics: Antiemetics; Aprepitant; Humans; Ifosfamide; Retrospective Studies; Sarcoma | 2023 |
[Errata: A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant].
Topics: Antiemetics; Aprepitant; Brain Diseases; Drug Interactions; Humans; Ifosfamide | 2023 |